Soleno Therapeutics, Inc. (SLNO) News
Filter SLNO News Items
SLNO News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
SLNO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SLNO News From Around the Web
Below are the latest news stories about SOLENO THERAPEUTICS INC that investors may wish to consider to help them evaluate SLNO as an investment opportunity.
Soleno Therapeutics, Inc. (NASDAQ:SLNO): When Will It Breakeven?We feel now is a pretty good time to analyse Soleno Therapeutics, Inc.'s ( NASDAQ:SLNO ) business as it appears the... |
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLCUp to $200 million financing, includes $50 million upfrontREDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan and security agreement with Oxford Finance LLC and its affiliates (Oxford) for up to $200 million. “This financing significantly strengthens our financial position, providing addition |
High Growth Tech Stocks to Watch in November 2024The United States market has shown robust performance recently, with a 2.0% increase over the last week and a substantial 32% climb in the past year, while earnings are projected to grow by 15% annually in the coming years. In this vibrant environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to maintain momentum alongside these promising market trends. |
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare ConferenceREDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time. A live audio webcast and replay of the fireside chat will be available in the Investors section on the |
FDA delays decision of Soleno’s Prader-Willi syndrome drugThe new Prescription Drug User Fee Act (PDUFA) date for diazoxide choline extended-release (DCCR) is slated for 27 March 2025. |
Kronos, Idorsia plan layoffs; PTC shelves ALS drugKronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC disclosed negative Phase 2 results for its ALS drug candidate utreloxastat. |
Soleno Tumbles 17% as FDA Extends Review Timeline for Prader-Willi TreatmentSoleno's FDA review delay pushes action date to March 2025, prompting a 17% premarket stock decline |
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi SyndromePDUFA target action date extended by three months to March 27, 2025REDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Wi |
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024, being held November 16-18, 2024 in Liverpool, UK. Detail |
Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |